Bilcare Ltd Stock Price Today (NSE: BI)
Fundamental Score
Bilcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bilcare Ltd share price today is ₹58.00, up +0.83% on NSE/BSE as of 17 June 2026. Bilcare Ltd (BI) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹200.42 (Cr). The 52-week high for BI share price is ₹116.00 and the 52-week low is ₹50.00. The company has a Return on Equity (ROE) of -5.58% and a debt-to-equity ratio of 1.48.
Bilcare Ltd Share Price Chart — NSE/BSE Historical Performance
Bilcare Ltd share price chart: -1.03% return over the past month. 52-week high ₹116.00, 52-week low ₹50.00.
Bilcare Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹63.19 | ₹66.50 | ₹61.90 | ₹66.02 | 5.32K (Cr) | |
| ₹70.00 | ₹70.00 | ₹63.10 | ₹63.20 | 8.39K (Cr) | |
| ₹63.50 | ₹64.00 | ₹62.04 | ₹62.06 | 2.10K (Cr) | |
| ₹62.50 | ₹63.33 | ₹62.20 | ₹62.20 | 1.15K (Cr) | |
| ₹61.50 | ₹62.50 | ₹61.00 | ₹62.12 | 4.36K (Cr) | |
| ₹65.00 | ₹66.70 | ₹60.05 | ₹61.59 | 11.09K (Cr) | |
| ₹64.80 | ₹64.80 | ₹62.56 | ₹63.99 | 627.00 (Cr) | |
| ₹64.05 | ₹66.00 | ₹62.64 | ₹63.01 | 1.22K (Cr) | |
| ₹62.07 | ₹65.95 | ₹62.07 | ₹63.80 | 1.56K (Cr) | |
| ₹65.00 | ₹66.45 | ₹62.61 | ₹63.04 | 6.82K (Cr) |
Bilcare Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹70.00 | ₹70.00 | ₹61.90 | ₹66.02 | -5.69% | |
| ₹66.60 | ₹74.00 | ₹60.05 | ₹62.06 | -6.82% | |
| ₹52.80 | ₹64.80 | ₹52.80 | ₹60.24 | +14.09% | |
| ₹58.00 | ₹62.27 | ₹50.00 | ₹52.76 | -9.03% | |
| ₹64.85 | ₹70.89 | ₹57.51 | ₹58.27 | -10.15% | |
| ₹80.70 | ₹80.77 | ₹63.01 | ₹67.20 | -16.73% | |
| ₹83.00 | ₹87.79 | ₹75.40 | ₹79.67 | -4.01% | |
| ₹108.00 | ₹108.00 | ₹76.15 | ₹85.50 | -20.83% | |
| ₹84.95 | ₹116.00 | ₹81.40 | ₹104.78 | +23.34% | |
| ₹69.00 | ₹100.99 | ₹66.10 | ₹82.39 | +19.41% | |
| ₹71.99 | ₹75.30 | ₹63.00 | ₹69.38 | -3.63% | |
| ₹73.25 | ₹80.00 | ₹67.15 | ₹69.04 | -5.75% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Bilcare Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bilcare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BI across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Strong Cash Generation (₹222.32 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
9 factors identified
Below-Average Return on Equity (-5.58%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (1.10%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-15.39%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-11.67%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-15.48% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Elevated Debt Levels (D/E: 1.48)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (0.09x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.04%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Bilcare Ltd vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare Bilcare Ltd with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Bilcare LtdBilcare Ltd...Selected✓ BI • 526853 | 6.9/100 | ₹58.00₹58 | ₹200.42₹200.42 | — — | -5.58%Poor -5.58% Poor | 1.10%Poor 1.10% Poor | 1.48Average 1.5 Average | 13.81%Good 13.81% Good | -15.48%Poor -15.48% Poor | 0.00% |
Syngene International LtdSyngene Interna... SYNGENE • 539268 | 41.6/100 | ₹460.40₹460 | ₹25985.68₹25985.68 | 55.50Average 55.5 Average | 10.53%Average 10.53% Average | 13.52%Average 13.52% Average | 0.12Excellent 0.1 Excellent | 5.71%Good 5.71% Good | 12.60%Good 12.60% Good | 0.19% |
Indegene LtdIndegene Ltd... INDGN • 544172 | 66.8/100 | ₹518.90₹519 | ₹12660.10₹12660.10 | 28.40Average 28.4 Average | 20.59%Excellent 20.59% Excellent | 24.80%Excellent 24.80% Excellent | 0.04Excellent 0.0 Excellent | 67.93%Excellent 67.93% Excellent | 34.59%Excellent 34.59% Excellent | 0.38% |
Suven Life Sciences LtdSuven Life Scie... SUVEN • 530239 | 6.5/100 | ₹267.15₹267 | ₹3927.58₹3927.58 | — — | -87.22%Poor -87.22% Poor | -86.96%Poor -86.96% Poor | 0.00Excellent 0.0 Excellent | -24.19%Poor -24.19% Poor | -12.00%Poor -12.00% Poor | 0.00% |
Vimta Labs LtdVimta Labs Ltd... VIMTALABS • 524394 | 65.8/100 | ₹456.70₹457 | ₹2716.50₹2716.50 | 36.39Average 36.4 Average | 19.43%Good 19.43% Good | 25.22%Excellent 25.22% Excellent | 0.02Excellent 0.0 Excellent | 58.03%Excellent 58.03% Excellent | 13.74%Good 13.74% Good | 0.16% |
Take Solutions LtdTake Solutions ... TAKE • 532890 | 19.5/100 | ₹30.93₹31 | ₹481.24₹481.24 | 120.61Average 120.6 Average | 644.12%Excellent 644.12% Excellent | 11.24%Average 11.24% Average | 0.00Excellent 0.0 Excellent | 38.14%Excellent 38.14% Excellent | — — | 0.00% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 40.6/100 | ₹57.14₹57 | ₹101.70₹101.70 | 104.85Average 104.8 Average | 0.64%Poor 0.64% Poor | 0.96%Poor 0.96% Poor | 0.00Excellent 0.0 Excellent | -2.33%Poor -2.33% Poor | 82.92%Excellent 82.92% Excellent | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 29.2/100 | ₹18.41₹18 | ₹25.54₹25.54 | 12.34Average 12.3 Average | 5.51%Poor 5.51% Poor | 8.27%Poor 8.27% Poor | 0.16Excellent 0.2 Excellent | -1.36%Poor -1.36% Poor | 8.33%Good 8.33% Good | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 7.2/100 | ₹24.45₹24 | ₹16.84₹16.84 | — — | -37.24%Poor -37.24% Poor | -11.58%Poor -11.58% Poor | 1.59Average 1.6 Average | — — | -32.27%Poor -32.27% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Ltd share price25985.68 Cr
- Indegene Ltd share price12660.10 Cr
- Suven Life Sciences Ltd share price3927.58 Cr
- Vimta Labs Ltd share price2716.50 Cr
- Take Solutions Ltd share price481.24 Cr
Bilcare Ltd Quarterly Performance
Latest quarterly metrics for BI — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-11.67%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-15.39%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-15.48%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
13.81%
Compounded annual net profit growth over 5 years
Bilcare Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BI — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Bilcare Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Bilcare Ltd (BI) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Bilcare Ltd
About BI (Bilcare Ltd)
Bilcare Ltd is a pioneering force at the intersection of healthcare research, analytics, and technology, dedicated to enhancing pharmaceutical integrity and patient safety globally.... The company distinguishes itself through its commitment to developing advanced packaging solutions that transcend traditional protective measures. Bilcare's multifaceted approach encompasses sophisticated research into material science, focusing on crafting innovative films, foils, and laminates specifically engineered to safeguard the efficacy and stability of solid-dose medications. Beyond mere physical protection, Bilcare is intensely invested in developing advanced anti-counterfeiting technologies and track-and-trace systems, empowering manufacturers to combat the pervasive threat of counterfeit drugs and ensure the authenticity of their products from production to patient consumption. Beyond its packaging solutions, Bilcare extends its expertise into the realm of clinical trial support. Bilcare facilitates the smooth execution of clinical studies through comprehensive trial management, tailored supplies, and logistical support. The company leverages cutting-edge data analytics to derive actionable insights from clinical trial data, accelerating the drug development process and improving trial outcomes. By integrating research, advanced data analytics, and innovative technologies, Bilcare plays a vital role in driving efficiency and transparency in clinical research. This holistic approach reinforces its position as a trusted partner for pharmaceutical companies seeking to navigate the complexities of drug development and regulatory compliance. Furthermore, Bilcare aggressively pursues research and development initiatives to push the boundaries of healthcare technology. It's a forward-thinking company aiming to revolutionize healthcare through material science, data, and pharmaceutical integrity. These ventures are fueled by a deep understanding of the evolving healthcare landscape and the escalating challenges faced by pharmaceutical manufacturers and patients. Bilcare invests in exploring new materials, developing advanced data analytics tools, and creating sophisticated track-and-trace technologies. This emphasis on innovation ensures that Bilcare remains at the forefront of the industry, consistently delivering cutting-edge solutions that address emerging needs and advance the frontiers of pharmaceutical integrity and patient safety.
Company Details
Key Leadership
Corporate Events
Latest News
BI Share Price: Frequently Asked Questions
What is the current share price of Bilcare Ltd?
Bilcare Ltd (BI) trades at ₹58.00 on NSE and BSE. Market cap ₹200.42 (Cr). Educational data only.
What is the P/E ratio of Bilcare Ltd?
Bilcare Ltd has a P/E of N/Ax vs industry average 45.95x.
What is the Bull Run score for Bilcare Ltd?
Bilcare Ltd has a Bull Run score of 6.9/100 based on 25+ financial parameters.
Does Bilcare Ltd pay dividends?
Bilcare Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Bilcare Ltd?
Bilcare Ltd has ROE of -5.58%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Bilcare Ltd?
Bilcare Ltd has debt-to-equity of 1.48.
Is Bilcare Ltd a good investment?
Bull Run gives Bilcare Ltd a score of 6.9/100. This is not investment advice — consult a SEBI-registered advisor.